The short answer
Discuss melatonin with the alprazolam prescriber. General product guidance warns about extra sedation, but a small direct trial did not find worse measured sedation than alprazolam alone.
What this answer covers
Oral melatonin with alprazolam; supervised perioperative immediate-dose studies differ from prolonged-release labels and chronic home use.
- Supplement or preparation
- Melatonin
- Medication ingredient
- alprazolam
Separate a precaution from trial findings
Melatonin product guidance cautions about sedative co-use. In an 80-person surgical study, adding melatonin did not significantly worsen measured sedation or amnesia relative to alprazolam alone.
Newer co-use evidence has a specific setting
Another study added melatonin to low-dose alprazolam and routine premedication before surgery and found less postoperative delirium. It was not a chronic insomnia safety trial and cannot establish that every combination is safe.
Agree on a plan rather than a gap
Tell the prescriber the melatonin dose, formulation and reason for use. No validated interval prevents possible impairment, and the surgical regimens are not instructions for home dosing.
Protect your alertness
Alprazolam can impair coordination and alertness. Avoid driving when affected. Seek urgent help for severe difficulty waking or breathing, and tell the prescriber about all other sedating medicines and alcohol.
Evidence and practical considerations
Side effects & toxicity
A conditional review is reasonable, but the broad claim of added sedation is not established by the direct trials.
- Exact scope
- Oral melatonin with alprazolam; supervised perioperative immediate-dose studies differ from prolonged-release labels and chronic home use. with Exact oral alprazolam; no blanket benzodiazepine metabolic or route transfer.
- Medication form and route
- oral; other cannabis routes only if explicitly discussed
- Timing or duration
- Exact duration and dose depend on source; single-dose and chronic use are distinguished.
What remains uncertain
- Small selected surgical populations, limited adverse-event power and other perioperative medicines; no universal home-use dose or spacing interval.
Factors that may matter: preparation and plant part; dose; other medicines; baseline alertness; clinical indication.
Read the supporting source summaries
Source 1: current product label
dailymed.nlm.nih.gov · Source check Sep 10, 2026
Population: Patients prescribed oral alprazolam.
CNS depression, impaired coordination and alertness can occur; concomitant CNS depressants require caution. Dependence and withdrawal risks require individualized tapering rather than abrupt cessation. Metabolism involves CYP3A; inhibitors and inducers may alter exposure. Not the same metabolic pathway profile as oxazepam or temazepam.
How this applies: Exact RxNorm ingredient and oral formulation confirmed in original label; use exact indication and metabolic boundaries.
Does not quantify the requested botanical interaction risks, prove every herb is sedating, or establish a protective supplement interval.
Source 2: product label
medicines.org.uk · Source check Sep 10, 2026
Population: People considering the specified supplement.
Can cause drowsiness and impair driving. Bedtime instructions are specific to this prolonged-release preparation. Co-administration with zolpidem increased impairment, but that is a different medicine.
How this applies: Preparation-specific context; not a directly measured alprazolam interaction.
No alprazolam study. Findings with zolpidem or this licensed formulation cannot define every melatonin product or a protective interval.
Source 3: original human study
pubmed.ncbi.nlm.nih.gov · Source check Sep 10, 2026
Population: Eighty selected surgical patients, twenty per arm.
Measured sedation and amnesia were comparable between combination and alprazolam alone.
How this applies: Apply only to exact medication, preparation and study exposure; comparator treatment is not co-use.
Small perioperative study, not powered for adverse events and not a chronic at-home safety test; exclusions included obesity and neuropsychiatric disease. Some pairwise significance reporting is internally inconsistent, so no superiority claim is relied on.
Source 4: original human study
pubmed.ncbi.nlm.nih.gov · Source check Sep 10, 2026
Population: 162 surgical patients aged 40-80 without baseline cognitive deficits.
Melatonin group had less postoperative delirium and improved measured sleep/cognitive outcomes.
How this applies: Apply only to exact medication, preparation and study exposure; comparator treatment is not co-use.
Single perioperative regimen with other drugs and anesthesia. Does not demonstrate chronic combination safety or a dose-spacing rule.
Research assessment: · Open full citations ↗
Review and change history
- Publication status
- Published research summary
- Clinical review
- Not yet recorded
| Date | Update |
|---|---|
| Article prepared | |
| Current exact claims adjudicated against captured originals and explicit comparator/co-use boundaries. | |
| Research summary published |
Article revision: 5ec59ffe61068755
This guide brings together the evidence records used by our interaction checker. Each finding retains its own preparation limits, research date, and source summaries.
Full citations require verification. Reading this answer and the source summaries does not.
Taking other supplements or medications?
Use the checker to explore your other combinations. Ask a pharmacist to review the exact products, amounts and medical conditions in your complete list.
Open the interaction checkerInformation, not medical advice. Do not change prescribed treatment based on this guide.